Remus IPO

Remus Pharmaceuticals Limited

₹1,15,000 /100 sharesMinimum Investment

Remus IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
--₹1,229.00₹1,797.00₹568.00 (46.22%)

Remus IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
17 May ‘23 - 19 May ‘23₹1,15,000100₹1,150 - ₹1,229
Issue SizeIPO Doc
47.69Cr
RHP PDF

About Remus

Remus Pharmaceuticals was established in 2015. It is involved in the distribution and marketing of pharmaceutical drugs in the form of Active Pharmaceutical Ingredients (APIs) and finished formulations. The company has a portfolio of 429 products sold under different brand names globally. Remus Pharma also has business-to-business supply agreements with 58 domestic distributors and 139 international distributors, allowing for distribution and contract manufacturing supply. ;
Parent Organisation
Remus Pharmaceuticals Limited
Founded
2015
Managing Director
Arpit Deepakkumar Shah

Strengths & Risks

  • Here are some strengths of Remus Pharmaceuticals Limited:
  • The company has a diversified presence in both international and domestic markets.
  • The company's business is supported by WHO GMP-compliant contract manufacturers, allowing it to manufacture approved formulations and market them under their own brand through a robust marketing network.
  • The company has increased its net profit and income consistently over the last 3 years.
  • Here are some risk factors associated with Remus Pharmaceuticals Limited
  • The company faces outstanding legal proceedings involving its directors and promoter, which may negatively impact its reputation and financial condition.
  • The company's dependency on a few large customers and suppliers poses a risk to its revenues and profitability.
  • The company operates in a highly regulated and controlled industry environment. Its ability to obtain and renew required regulatory approvals and registrations is crucial for the business.
  • The company's failure to maintain the quality standards of its products or keep up with technological developments could harm its business and financial condition.
  • The company's global operations expose it to numerous and conflicting legal and regulatory requirements. Any violation of these regulations may have a detrimental impact on its business.
  • Global economic, political, and social conditions may harm the company's ability to conduct business.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular1150 - 1229₹2 Lakh
High Networth Individual1150 - 1229₹2 - 5 Lakh
For Remus SME IPO, eligible investors can apply as Regular.
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.5.1
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ

ABOUT GROWW